

Automobiles | Company Research

27 March 2015

Hold Downgrade

业绩无惊喜,下调评级至持有

广汽集团 (2238 HK)

	2013	2014	2015E	2016E	2017E
Revenue (Rmbm)	18,824	22,376	25,688	28,821	31,934
YoY (%)	45.21	18.87	14.80	12.20	10.80
Net income (Rmbm)	2,529	2,926	3,114	3,549	3,898
YoY (%)	133.94	20.07	6.40	13.98	9.83
EPS (Rmb)	0.41	0.49	0.53	0.60	0.66
Diluted EPS (Rmb)	0.41	0.49	0.53	0.60	0.66
ROE (%)	7.78	8.81	8.62	9.08	9.23
Debt/asset (%)	41.02	42.01	43.37	44.69	45.89
Dividend Yield (%)	2.84	2.84	2.99	3.41	3.74
PE (x)	13.67	11.39	10.70	9.39	8.55
PB (x)	1.06	1.00	0.92	0.85	0.79
EV/Ebitda (x)	7.61	6.70	6.28	5.55	5.03

Note: Diluted EPS is calculated as if all outstanding convertible securities, such as convertible preferred shares, convertible debentures, stock options and warrants, were exercised..

业绩超预期,但分红派息不及预期。广汽集团 2014 年收入约人民币 224 亿元(同比增长 18.9%),净利 润约人民币 29 亿元(同比增长 15.7%)。归属公司的净利润约人民币 32 亿元(同比增长 20.1%),全 年每股净利润为人民币 0.49,超过我们预测的人民币 0.44 元。我们认为,公司自主乘用车品牌传祺的快 速发展带动了收入和盈利端的增长。2014 年每股分红为人民币 0.16 元,股息支付率从 2013 年的 39%下 滑至 2014 年的 33%,低于我们的预期。


毛利率上升,净利率持平。由于传祺 GS5 较高的毛利率贡献,广汽集团的整体毛利率从 2013 年的 10.6%上升至 2014 年的 11.4%。2014 年,合资公司的收益贡献同比增长 4%至人民币 42 亿元。尽管销 售和营销费用同比增长 72%;但由于公司完成了人民币约 1.6 亿元的一次性收购收益以及约人民币 1.1 亿 元的投资收益,其他收益或损失项从 2013 年的净损失约 4.3 亿元提升至 2014 年的净收益约 3.5 亿元。受此影响,净利率在 2014 年稳定在 13%左右。杠杆率从 2013 年的 29.4%下滑至 2014 年的 28.4%; ROE 与去年相比增长 1%至 9.3%。

疲软的销量增长势头预计将持续。尽管广汽吉奥销量出现强劲反弹(销量同比增速从 2014 年的-29.3%提高至 2015 年 1-2 月的 130.1%) · 但广汽的整体销售增速却从从 2014 的 16.7%下滑至 2015 年 1-2 月的 8.9%。我们认为销量的下滑 · 主要是受几大品牌销量表现不佳的影响;其中包括广汽菲亚特(销量同比增速从 2014 年的 40.8%下滑至 2015 年 1-2 月的-29.3%) · 广汽丰田(销量同比增速从 2014 年的 23.4%下滑至 2015 年 1-2 月的 0.7%) · 广汽自主乘用车品牌(销量同比增速从 2014 年的 23.6%下滑至 2015 年 1-2 月的 8.4%)以及广汽三菱(销量同比增速从 2014 年的 46.9%下滑至 2015 年 1-2 月的 3.6%)。广汽本田销量保持稳定 · 2015 年 1-2 月销量增速为 12%(2014 年销量增速为 10%)。我们认为 · 由于缺乏具有竞争性的 SUV 车型 · 公司疲软的销量增长势头预计将会持续。我们预计在 2015 年 · 广汽集团的总销量增速将会放缓至 10%左右。

下调至持有。我们维持 2015 年的每股盈利预测人民币 0.53 元(同比增长 6%) ·2016 年的每股盈利预测人民币 0.60 元(同比增长 14%) ·并预测 2017 年的每股盈利预测为人民币 0.66 元(同比增长 10%)。我们维持目标价港币 7.67 元。当前股价对应 10.7/9.4/8.6 倍 2015/16/17 年市盈率。鉴于 8% 的上涨空间,我们把评级从增持下调至持有。

Market Data: Mar, 26	
Closing Price (HK\$)	7.10
Price Target (HK\$)	7.67
HSCEI	11,920
HSCCI	4,515
52-week High/Low (HK\$)	9.87/6.58
Market Cap (US\$m)	5,895
Market Cap (HK\$m)	45,689
Shares Outstanding (m)	6,435
Exchange Rate (Rmb-HK\$)	1.26
Duine Deufeumennes Cheute	

Price Performance Chart:



Source: Bloomberg Analyst Titus Wu A0230511040056 ARG344 wutao@swsresearch.com

Contact Annie Ni

niyj@swsresearch.com

Related Reports

" GEELY AUTOMOBILE HOLDINGS (175:HK) - Sales heat up" Feb 26,2015

The company does not hold any equities or derivatives of the listed company mentioned in this report ("target"), but then we shall provide financial advisory services subject to the relevant laws and regulations. Any affiliates of the company may hold equities of the target, which may exceed 1 percent of issued shares subject to the relevant laws and regulations. The company may also provide investment banking services to the target. The Company fulfills its duty of disclosure within its sphere of knowledge. The clients may contact compliance@swsresearch.com for relevant disclosure materials or log into www.swsresearch.com under disclosure column for further information. The clients shall have a comprehensive understanding of the disclosure and disclaimer upon the last page

Automobiles | Company Research



Investment Highlights

Results beat but dividend missed. Guangzhou Automobile Group (GAC) reported 2014 revenue of Rmb22.4bn (+18.9% YoY) and net profit of Rmb2.9bn (+15.7% YoY), driven by the rapid development of its independent passenger car brand *Trumpchi*. Net profit attributable to shareholders reached Rmb3.2bn (+20.1% YoY) and full-year EPS arrived at Rmb0.49, exceeding our expectation of Rmb0.44. Annual dividend of Rmb0.16/share was announced in 2014, leading to a 33% dividend payout ratio (vs 39% in 2013).

Mixed margin performance. GAC's total gross margin increased from 10.6% in 2013 to 11.4% in 2014, thanks to its improving product mix towards higher-margin Trumpchi GS5. Share of profits of JVs and associates grew by 4% YoY to Rmb4.2bn in 2014. Other gains or losses increased from -Rmb433mn in 2013 to Rmb345mn 2014, primarily due to a one-off gain on acquisition of Shengyang-Hino of Rmb157mn and larger investment income on financial assets of Rmb107mn, which offset a huge increase in selling and marketing expenses (+72% YoY) and resulted in a relatively flat net margin of 13% in 2014. The company reported a healthier balance sheet, with leverage ratio edging down from 29.4% in 2013 to 28.4% in 2014 and ROE increasing by 1% to 9.3% in 2014.

Weak sales likely to continue. Tough GAC-Gonow witnessed a strong sales rebound (+130.1% YoY in Jan-Feb 2015 vs -29.3% YoY in 2014), GAC's overall sales growth decelerated from +16.7% YoY in 2014 to +8.9% YoY in Jan-Feb 2015, dragged down by sluggish sales in GAC-Fiat (-29.3% YoY in Jan-Feb 2015 vs +40.8% YoY in 2014), GAC-Toyota (+0.7% YoY in Jan-Feb 2015 vs +23.4% YoY in 2014), GAC-local brands (+8.4% YoY in Jan-Feb 2015 vs +23.6% YoY in 2014) and GAC-Mitsubishi (+33.6% YoY in Jan-Feb 2015 vs +46.9% in 2014). Sales growth for GAC-Honda remained stable, up 12% YoY in Jan-Feb (vs +10% in 2014). We believe the company's weak sales growth momentum will likely continue, mainly due to lack of competing SUV models. We expect GAC's total sales growth to moderate to c.10% in 15E.

Downgrade to Hold. We maintain our EPS forecasts of Rmb0.53 in 15E (+6% YoY), Rmb0.60 in 16E (+14% YoY), and forecast EPS of Rmb0.66 in 17E (+10% YoY). We maintain our target price of HK\$7.67. The current share price implies 10.7x 14E PE, 9.4x 15E PE and 8.6x 16E PE. With 8% upside, we downgrade our rating from Outperform to Hold.

Ĭ

APPENDIX

Table 1: Consolidated Income Statement

Rmbm	2013	2014	2015E	2016E	2017E
Revenue	18,824	22,376	25,688	28,821	31,934
Cost of Sales	(16,830)	(19,829)	(22,708)	(25,421)	(28,070)
Gross Profit	1,994	2,547	2,980	3,401	3,864
Other Income	(433)	345	257	288	319
Distribution expenses	(1,071)	(1,841)	(2,183)	(2,450)	(2,714)
Administrative expenses	(1,713)	(1,874)	(1,644)	(1,787)	(1,948)
EBITDA	102	505	779	891	1,028
EBIT	(848)	(504)	(310)	(261)	(190)
Share of results of associates	3,100	3,213	3,448	3,951	4,361
Jointly controlled entities	920	968	773	812	852
Finance Costs	(169)	(307)	(384)	(514)	(670)
Profit before tax	2,629	3,053	3,247	3,701	4,065
Income tax expense	(101)	(126)	(133)	(152)	(167)
Profit for the year	2,529	2,926	3,114	3,549	3,898
Minority interests	(124)	(259)	(275)	(314)	(345)
Equity holders of the parent	2,653	3,185	3,389	3,863	4,243

Source: SWS Research

Table 2: Consolidated Cash Flow Statement

Rmbm	2013	2014	2015E	2016E	2017E
Profit before taxation	2,529	2,926	3,114	3,549	3,898
Plus: Depr. and amortisation	951	1,009	1,089	1,152	1,217
Share of results of JCEs	(4,020)	(3,213)	(3,448)	(3,951)	(4,361)
Share of results of Associates	-	(968)	(773)	(812)	(852)
Finance cost	645	745	805	928	1,073
Change in working capital	566	210	573	318	286
Others	(255)	(554)	(658)	(793)	(951)
CF from operating activities	548	348	414	129	74
CAPEX	(1,904)	(1,850)	(1,760)	(2,035)	(2,221)
Other CF from investing activities	2,612	(1,402)	675	594	520
CF from investing activities	708	(3,252)	(1,085)	(1,441)	(1,702)
Net change in liabilities	4,041	138	2,147	2,540	3,011
Dividend and interest paid	(538)	(1,030)	(1,085)	(1,236)	(1,358)
Other CF from financing activities	9	-	-	-	-
CF from financing activities	3,512	(909)	1,062	1,304	1,653
Net cash flow	4,767	(3,813)	391	(8)	25

Source : SWS Research

SWS

Ē

Table 3: Consolidated Balance Sheet

Rmbm	2013	2014	2015E	2016E	2017E
Current Assets	26,514	26,974	27,762	28,413	29,129
Bank balances and cash	19,040	18,365	18,081	17,479	16,984
Trade and other receivables	4,725	5,515	6,248	7,086	7,898
Inventories	2,036	2,661	2,978	3,369	3,744
Other current assets	3	-	-	-	-
Long-term investment	18,425	18,693	25,505	30,707	36,372
PP&E	8,517	10,037	10,369	11,692	13,131
Intangible and other assets	4,388	6,667	5,809	6,073	6,367
Total Assets	57,843	62,372	69,446	76,884	85,001
Current Liabilities	18,059	20,222	23,824	27,740	32,047
Borrowings	9,397	9,541	11,449	13,738	16,486
Trade and other payables	8,637	10,645	12,336	13,957	15,512
Other current liabilities	25	37	40	44	49
Long-term liabilities	5,668	5,981	6,292	6,619	6,963
Total Liabilities	23,727	26,203	30,116	34,359	39,010
Share Capital	6,435	6,435	6,435	6,435	6,435
Reserves	26,876	28,938	32,124	35,257	38,653
Minority interests	805	796	771	834	902
Total Liabilities and equity	57,843	62,372	69,446	76,884	85,001

Source: SWS Research

Table 4: Key Financial Ratios

	2013	2014	2015E	2016E	2017E
Ratios per share (Rmb)					
Earnings per share	0.41	0.49	0.53	0.60	0.66
Operating CF per share	0.09	0.05	0.06	0.02	0.01
Dividend per share	0.16	0.16	0.17	0.19	0.21
Net assets per share	5.30	5.62	6.11	6.61	7.15
Key Operating Ratios (%)					
ROE	7.78	8.81	8.62	9.08	9.23
Gross profit margin	10.60	11.38	11.60	11.80	12.10
EBITDA Margin	0.54	2.26	3.03	3.09	3.22
EBIT Margin	(4.51)	(2.25)	(1.21)	(0.90)	(0.59)
Growth rate of Revenue (YoY)	45.21	18.87	14.80	12.20	10.80
Growth rate of Profit (YoY)	133.94	20.07	6.40	13.98	9.83
Debt-to-asset ratio	41.02	42.01	43.37	44.69	45.89
Turnover rate of net assets	0.55	0.62	0.65	0.68	0.69
Turnover rate of total assets	0.33	0.36	0.37	0.37	0.38
Effective tax rate (%)	3.83	4.13	4.10	4.10	4.10
Dividend yield (%)	2.84	2.84	2.99	3.41	3.74

Source: SWS Research



Information Disclosure :

The views expressed in this report accurately reflect the personal views of the analyst. The analyst declares that neither he/she nor his/her associate serves as an officer of nor has any financial interests in relation to the listed corporation reviewed by the analyst. None of the listed corporations reviewed or any third party has provided or agreed to provide any compensation or other benefits in connection with this report to any of the analyst, the Company or the group company(ies). A group company(ies) of the Company confirm that they, whether individually or as a group (i) are not involved in any market making activities for any of the listed corporation reviewed; or (ii) do not have any individual employed by or associated with any group company(ies) of the Company serving as an officer of any of the listed corporation reviewed; or (iii) do not have any financial interest in relation to the listed corporation reviewed or (iv) do not, presently or within the last 12 months, have any investment banking relationship with the listed corporation reviewed.

Undertakings of the Analyst

I (We) am (are) conferred the Professional Quality of Securities Investment Consulting Industry by the Securities Association of China and have registered as the Securities Analyst. I hereby issue this report independently and objectively with due diligence, professional and prudent research methods and only legitimate information is used in this report. I am also responsible for the content and opinions of this report. I have never been, am not, and will not be compensated directly or indirectly in any form for the specific recommendations or opinions herein.

Disclosure with respect to the Company

The company is a subsidiary of Shenwan Hongyuan Securities. The company is a qualified securities investment consulting institute approved by China Securities Regulatory Commission with the code number ZX0065.

Releasing securities research reports is the basic form of the securities investment consulting services. The company may analyze the values or market trends of securities and related products or other relevant affecting factors, provide investment analysis advice on securities valuation/ investment rating, etc. by issuing securities research reports solely to its clients.

The Company fulfills its duty of disclosure within its sphere of knowledge. The clients may contact <u>compliance@swsresearch.com</u> for the relevant disclosure materials or log into <u>www.swsresearch.com</u> for the analysts' qualifications, the arrangement of the quiet period and the affiliates' shareholdings.

Introduction of Share Investment Rating

Security Investment Rating :

When measuring the difference between the markup of the security and that of the market's benchmark within six months after the release of this report, we define the terms as follows:

Trading BUY: Share price performance is expected to generate more than 20% upside over a 6-month period.

BUY: Share price performance is expected to generate more than 20% upside over a 12-month period.

Outperform: Share price performance is expected to generate between 10-20% upside over a 12-month period.

Hold: Share price performance is expected to generate between 10% downside to 10% upside over a 12-month period.

Underperform: Share price performance is expected to generate between 10-20% downside over a 12-month period.

SELL: Share price performance is expected to generate more than 20% downside over a 12-month period. Industry Investment Rating:

When measuring the difference between the markup of the industry index and that of the market's benchmark within six months after the release of the report, we define the terms as follows:

Overweight: Industry performs better than that of the whole market;

Equal weight : Industry performs about the same as that of the whole market ;

Underweight : Industry performs worse than that of the whole market.

We would like to remind you that different security research institutions adopt different rating terminologies and rating standards. We adopt the relative rating method to recommend the relative weightings of investment. The clients' decisions to buy or sell securities shall be based on their actual situation, such as their portfolio structures and other necessary factors. The clients shall read through the whole report so as to obtain the complete opinions and information and shall not rely solely on the investment ratings to reach a conclusion. The Company employs its own industry classification system. The industry classification is available at our sales personnel if you are interested.

HSCEI is the benchmark employed in this report.

Disclaimer :

This report is to be used solely by the clients of SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities, hereinafter referred to as the "Company"). The Company will not deem any other person as its client notwithstanding his receipt of this report.

This report is based on public information, however, the authenticity, accuracy or completeness of such information is not warranted by the Company. The materials, tools, opinions and speculations contained herein are for the clients' reference only, and are not to be regarded or deemed as an invitation for the sale or purchase of any security or other investment instruments.

The clients understand that the text message reminder and telephone recommendation are no more than a brief communication of the research opinions, which are subject to the complete report released on the Company's website (<u>http://www.swsresearch.com</u>). The clients may ask for follow-up explanations if they so wish.

The materials, opinions and estimates contained herein only reflect the judgment of the Company on the day this report is released. The prices, values and investment returns of the securities or investment instruments referred to herein may fluctuate. At different periods, the Company may release reports which are inconsistent with the materials, opinions and estimates contained herein.

Save and except as otherwise stipulated in this report, the contactor upon the first page of the report only acts as the liaison who shall not provide any consulting services.

The clients shall consider the Company's possible conflict of interests which may affect the objectivity of this report, and shall not base their investment decisions solely on this report. The clients should make investment decisions independently and solely at your own risk. Please be reminded that in any event, the company will not share gains or losses of any securities investment with the clients. Whether written or oral, any commitment to share gains or losses of securities investment is invalid. The investment and services referred to herein may not be suitable for certain clients and shall not constitute personal advice for individual clients. The Company does not ensure that this report fully takes into consideration of the particular investment objectives, financial situations or needs of individual clients. The Company strongly suggests the clients to consider themselves whether the opinions or suggestions herein are suitable for the clients' particular situations; and to consult an independent investment consultant if necessary.

Under no circumstances shall the information contained herein or the opinions expressed herein forms an investment recommendation to anyone. Under no circumstances shall the Company be held responsible for any loss caused by the use of any contents herein by anyone. Please be particularly cautious to the risks and exposures of the market via investment. Independent investment consultant should be consulted before any investment decision is rendered based on this report or at any request of explanation for this report where the receiver of this report is not a client of the Company.

The Company possesses all copyrights of this report which shall be treated as non-public information. The Company reserves all rights related to this report. Unless otherwise indicated in writing, all the copyrights of all the materials herein belong to the Company. In the absence of any prior authorization by the Company in writing, no part of this report shall be copied, photocopied, replicated or redistributed to any other person in any form by any means, or be used in any other ways which will infringe upon the copyrights of the Company. All the trademarks, service marks and marks used herein are trademarks, service marks or marks of the Company, and no one shall have the right to use them at any circumstances without the prior consent of the Company.

This report may be translated into different languages. The Company does not warrant that the translations are free from errors or discrepancies. This report is for distribution in Hong Kong only to persons who fall within the definition of professional investors whether under the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong) (the "SFO") or the Securities and Futures (Professional Investor) Rules (Chapter 571D of the laws of the Hong Kong under the SFO).

This report is for distribution in the United Kingdom only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) order 2001 (as amended) (the "Order") or (ii) are persons falling within Article 49(2)(a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc") of the Order (All such persons together being referred to as "Relevant Persons"). This document is directed only at Relevant Persons. Other Persons who are not Relevant Persons must not act or rely upon this document or any of its contents.

Disclaimer

This report was prepared, approved, published and distributed by the SWS Research Co., Ltd (subsidiary of Shenwan Hongyuan Securities) located outside of the United States (a "non-US Group Company"). This report is distributed in the U.S. by Enclave Capital LLC, a U.S. registered broker dealer, on behalf of SWS Research Co., Ltd only to major U.S. institutional investors (as defined in Rule 15a-6 under the U.S. Securities Exchange Act of 1934 (the "Exchange Act")) pursuant to the exemption in Rule 15a-6 and any transaction effected by a U.S. customer in the securities described in this report must be effected through Enclave Capital LLC (19 West 44th Street, suite 1700, New York, NY 10036).

Neither the report nor any analyst who prepared or approved the report is subject to U.S. legal requirements or the Financial Industry Regulatory Authority, Inc. ("FINRA") or other regulatory requirements pertaining to research reports or research analysts. No non-US Group Company is registered as a broker-dealer under the Exchange Act or is a member of the Financial Industry Regulatory Authority, Inc. or any other U.S. self-regulatory organization.

The information has been compiled or arrived from sources believed to be reliable and in good faith, but no representation or warranty, express or implied is made as to their accuracy, completeness or correctness. SWS Research Co., Ltd has not verified the factual accuracy, assumptions, calculations or completeness of the information. Accordingly, SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) accepts no liability whatsoever for any direct or consequential loss or damage arising from (i) the use of this communication (ii) reliance of any information contained herein, (iii) any error, omission or inaccuracy in any such Information or (iv) any action resulting there from. SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) provides the information for the purpose of the intended recipient's analysis and review. Accordingly you are advised to verify the factual accuracy, assumptions, calculations or completeness of the information.

Analyst Certification

Each of the analysts identified in this report certifies, with respect to the companies or securities that the individual analyses, that (1) the views expressed in this report reflect his or her personal views about all of the subject companies and securities and (2) no part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this report.

Important US Regulatory Disclosures on Subject Companies

This material was produced by SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) solely for information purposes and for the use of the recipient. It is not to be reproduced under any circumstances and is not to be copied or made available to any person other than the recipient. It is distributed in the United States of America by Enclave Capital LLC and elsewhere in the world by SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) or an authorized affiliate of SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities). This document does not constitute an offer of, or an invitation by or on behalf of SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) or its affiliates or any other company to any person, to buy or sell any security. The information contained herein has been obtained from published information and other sources, which SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) or completeness of any such information. All estimates, expressions of opinion and other subjective judgments contained herein are made as of the date of this document. Emerging securities markets may be subject to risks significantly higher than more established markets. In particular, the political and economic environment, company practices and wolumes may be subject to significant variations. The ability to assess such risks may also be limited due to significantly lower information quantity and quality. By accepting this document, you agree to be bound by all the foregoing provisions.

1. SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) or its Affiliates have not recently been the beneficial owners of 1% or more of the securities mentioned in this report.

2. SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) or its Affiliates have not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months.

3. SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) or its Affiliates have not received compensation for investment banking services from the issuer of these securities in the past 12 months and do not expect to receive compensation for investment banking services from the issuer of these securities within the next three months.

4. However, one or more person of SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) or its affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon either on their own account or on behalf of their clients.

5. As of the publication of this report Enclave Capital LLC, does not make a market in the subject securities.

6. SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) or its Affiliates may, to the extent permitted by law, act upon or use the above material or the conclusions stated above or the research or analysis on which they are based before the material is published to recipients and from time to time provide investment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securities business from, any entity referred to in this report

Distribution in Singapore

If distributed in Singapore, this report is meant only for Accredited Investors and Institutional Investors as defined under Section 4A of the Securities and Futures Act of Singapore. If you are not an Accredited Investor or an Institutional Investor, you shall ignore the report and its contents. The Singapore recipients of the report are to contact the Singapore office of Shenyin Wanguo Singapore Private Limited at 65-6323-5208, or 65-6323-5209 in respect of any matters arising from, or in connection with, the report.

rom, or in connection with, the report.